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Background: Various therapeutic effects of fenugreek (Trigonella foenum-graecum L.) on metabolic disorders have
been reported. However, the bitterness of fenugreek makes it hard for humans to eat sufficient doses of it for
achieving therapeutic effects. Fenugreek contains bitter saponins such as protodioscin. Fenugreek with reduced
bitterness (FRB) is prepared by treating fenugreek with beta-glucosidase. This study has been undertaken to
evaluate the effects of FRB on metabolic disorders in rats.
Methods: Forty Sprague–Dawley rats were fed with high-fat high-sucrose (HFS) diet for 12 week to induce mild
glucose and lipid disorders. Afterwards, the rats were divided into 5 groups. In the experiment 1, each group (n = 8)
was fed with HFS, or HFS containing 2.4% fenugreek, or HFS containing 1.2%, 2.4% and 4.8% FRB, respectively, for
12 week. In the experiment 2, we examined the effects of lower doses of FRB (0.12%, 0.24% and 1.2%) under the
same protocol (n = 7 in each groups).
Results: In the experiment 1, FRB dose-dependently reduced food intake, body weight gain, epididymal white
adipose tissue (EWAT) and soleus muscle weight. FRB also lowered plasma and hepatic lipid levels and increased
fecal lipid levels, both dose-dependently. The Plasma total cholesterol levels (mmol/L) in the three FRB and Ctrl
groups were 1.58 ± 0.09, 1.45 ± 0.05*, 1.29 ± 0.07* and 2.00 ± 0.18, respectively (*; P< 0.05 vs. Ctrl). The Hepatic total
cholesterol levels (mmol/g liver) were 0.116 ± 0.011, 0.112 ± 0.006, 0.099 ± 0.007* and 0.144 ± 0.012, respectively
(*; P< 0.05 vs. Ctrl). The calculated homeostasis model assessment as an index of insulin resistance (HOMA-IR)
indicated 0.52 ± 0.04*, 0.47 ± 0.06*, 0.45 ± 0.05* and 1.10 ± 0.16, respectively (*; P< 0.05 vs. Ctrl). None of the FRB
groups showed any adverse effect on the liver, kidney or hematological functions. In the experiment 2, no
significant difference of food intake was observed, while the 1.2% FRB group alone showed nearly the same effects
on glucose and lipid metabolism as in the experiment 1.
Conclusions: Thus we have demonstrated that FRB (1.2 ~ 4.8%) prevents diet-induced metabolic disorders such as
insulin resistance, dyslipidemia and fatty liver.
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Recently, under the rapid economic development in
advanced countries, lifestyle diseases including metabolic
disorders are expanding. The principle of the basic
therapeutic policy for these diseases consists of improve-
ment of diet habits and enhancement of physical activ-
ities. However, it is difficult to control and change one’s* Correspondence: emuraki@ncnp.go.jp
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reproduction in any medium, provided the orestablished life styles. In such cases, functional foods
with therapeutic effects on metabolic disorders are very
helpful for the improvement of lifestyle diseases.
Various medicinal properties of fenugreek (Trigonella
foenum-graecum L.) have been described earlier and its
use in traditional Indian medicine is well known [1]. In
recent years, fenugreek has been used in Western coun-
tries as a medicinal herb or as a spice. It has been
reported that fenugreek reduced serum cholesterol level
[2,3], and improved blood glucose level and lipid
metabolism in disease model animals of type 1 diabetesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[4,5] and streptozotocin [6]. Recently, it has been
reported that some active components of fenugreek, 4-
hydroxyisoleucine (4-OH-Ile) [7,8] and galactomannan
[9,10], inhibited the elevation of blood glucose level and
improved lipid metabolism in vivo. We have also
reported that fenugreek reduced lipid levels in plasma
and liver, leading to the improvement of insulin sensitiv-
ity in rats with metabolic disorders induced by a high-fat
high-sucrose diet [11]. In our recent experiments, fenu-
greek dose-dependently inhibited the lipid accumulation
in liver by increasing the excretion of lipid and bile acids
in feces. An effective, safe and tolerable dose of fenu-
greek was about 2.5% (w/w) [12]. However, the strong
bitterness of fenugreek makes it difficult for humans to
eat sufficient amount of fenugreek for the improvement
of metabolic disorders. The main component of bitter-
ness in fenugreek is protodioscin [13] Additional file 1].
So protodioscin was enzymatically converted into dios-
cin with no bitter taste.
The purpose of this study was to examine whether
fenugreek with reduced bitterness (FRB) has such effects
on diet-induced metabolic disorders as unmodified fenu-
greek, and to determine the most effective and tolerable
dose of FRB.Methods
Materials
Fenugreek and FRB were provided by House Foods
(Chiba, Japan). FRB was made by adding cellulase enzyme
(SPEZYME CP; Genencor, CA, USA) to fenugreek [14].
82% of protodioscin was converted into dioscin in the
FRB used for the experiment 1, and 96% of protodioscinTable 1 The diets1 of experiment 1 and 2
(g) Ctrl Fen
0.12%
Lard2 260.000 258.626 259.912
Milk casein2 200.000 193.205 199.653
Sucrose2 312.000 312.000 312.000
α-Corn starch2 32.487 32.487 32.487
β-Corn starch2 97.461 92.345 97.050
Vitamin mixture3 10.000 10.000 10.000
Mineral mixture4 35.000 34.264 34.953
Cellulose powder2 50.000 40.045 49.695
L-Cystin5 3.000 3.000 3.000
t-Butylhydroquinone5 0.052 0.052 0.052
Fenugreek6 - 23.976 -
FRB7 - - 1.199
Ctrl: Control group, Fen: Fenugreek group. 1Based on the AIN-93 G and modified. 2,
on the AIN-93 formation, and added with tartaric acid choline. 4Mineral mixture wa
Industries, Osaka, Japan. 6,7Purchased from House Foods Corp., Somatech Center, Cwas converted into dioscin in the FRB used for the experi-
ment 2. The enzyme also digested insoluble fiber fraction,
hemicellulose and cellulose in fenugreek, and increased
water-soluble fiber fractions in FRB. And the high molecu-
lar weight galactomannan (average molecular weight
2,000,000) in fenugreek was converted to the low molecu-
lar weight galactomannan (average molecular weight
500,000) in FRB. Thus FRB has a lower viscosity than
fenugreek. As a result, FRB contains a larger amount of
dioscin and soluble fiber fractions as compared with fenu-
greek itself.Animal care
Three-week-old male, Sprague–Dawley rats were
obtained from CLEA Japan, Inc. (Tokyo, Japan). The rats
were housed individually in stainless steel wire-bottom
cages in a room maintained at 22 ± 2°C and 55 ± 5% rela-
tive humidity with a 12 h cycle of light and dark. Tap
water was given them freely throughout the experiment.
The rats were fed a commercial diet (CE-2; CLEA Japan)
for 1 week before proceeding to diet-induced metabolic
disorders. Diets used in this study were high-fat high-
sucrose (HFS; lard 50%kcal, sucrose 25%kcal) diets based
on the modified version of the AIN-93 G [15]. The rats
were fed high-fat high-glucose (HFS) diet ad libitum for
12 week to induce metabolic disorders. In both experi-
ments 1 and 2, the rats with diet-induced metabolic dis-
orders were randomly divided into 5 groups of 7–8 rats
each. Each experimental group was fed with either of
the experimental diets shown in Table 1 for an add-
itional 12 week period. After the 12 week, the rats were
individually transferred into metabolic cages, and their
feces were separately collected for 1 day. At the end ofFRB
0.24% 1.2% 2.4% 4.8%
259.823 259.115 258.231 256.461
199.306 196.529 193.059 186.118
312.000 312.000 312.000 312.000
32.487 32.487 32.487 32.487
96.638 93.347 89.232 81.004
10.000 10.000 10.000 10.000
34.907 34.535 34.070 33.139
49.389 46.947 43.893 37.787
3.000 3.000 3.000 3.000
0.052 0.052 0.052 0.052
- - - -
2.398 11.988 23.976 47.952
3,4Purchased from Oriental Yeast Co.,Tokyo, Japan. 3Vitamin mixture was based
s based on the AIN-93 G formation. 5Purchased from Wako Pure Chemical
hiba, Japan. 7FRB: Fenugreek with reduced bitterness.
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pentobarbital sodium (100 mg/kg, ip) anesthesia. Their
blood samples were collected from the abdominal aorta,
and the plasma was separated by means of centrifuga-
tion (2,000 × g for 20 min at 4°C) and stored at −30°C
until analyzed. Immediately after the collection of the
blood samples, the livers, the solei and the epididymal
white adipose tissues (EWAT) were excised, weighed
and stored at −30°C for further analyses.
The experimental protocol was approved by the Insti-
tutional Animal Care and Use Committee of Josai
University.
Experimental diets
The experimental diets of the experiment 1: HFS (Ctrl
group) as control, the HFS containing 2.4% fenugreek
(Fen group), 1.2, 2.4 and 4.8% FRB (Table 1).
The experimental diets of the experiment 2: HFS (Ctrl
group) as control, the HFS containing 2.4% fenugreek
(Fen group), 0.12, 0.24 and 1.2% FRB.
Water-soluble dietary fiber (SDF) and insoluble dietary
fiber (IDF) were measured by the Modified Prosky
Method [16]. Fenugreek contains 9.4% (w/w) of SDF and
32.1% (w/w) of IDF, whereas FRB in the experiment 1
and 2 contained 13.4% (w/w) of SDF and 12.6% (w/w) of
IDF, and 20.8% (w/w) of SDF and 12.7% (w/w) of IDF,
respectively.
Oral glucose tolerance tests and intraperitoneal insulin
tolerance tests
At the10th wk, the rats were deprived of food for 12 h,
and afterwards they were submitted to an oral glucose
tolerance test (OGTT: 2 g/kg b.w. glucose). And at the
11th wk, an intraperitoneal insulin tolerance test (IPITT:
0.75 U/kg b.w. human regular insulin) was performed.
We measured blood glucose concentrations by Ascen-
siaTM DexterZII (Bayer Medical, Tokyo, Japan) using tail
blood samples at 0, 30, 60 and 120 min after the glucose
administration, and at 0, 15, 30, 60 and 120 min after
the insulin administration. Likewise, we measured
plasma insulin concentrations by commercial kit (Rat In-
sulin ELISA KIT, Shibayagi, Co., Gunma, Japan) using
separated tail plasma samples at 0, 30, 60 and 120 min
after the glucose administration.
Blood analysis
Plasma triglyceride, total cholesterol, AST and ALT were
measured by colorimetric slides using the Fuji Dri-Chem
3500 (Fujifilm Corp., Tokyo, Japan).
Hepatic and fecal lipid concentrations
The hepatic and fecal lipids were extracted in accord-
ance with the method of Bligh and Dyer [17] and the
method of Folch [18], respectively. Each extract wassolubilized by Triton-X100 (Wako Pure Chemical Indus-
tries, Osaka, Japan), and the lipid concentrations were
determined enzymatically using commercial kits (Trigly-
cerides E-Test Wako, Cholesterol E-Test Wako, Total
Bile Acid Test Wako; Wako Pure Chemical Industries).
Statistical analysis
All data are expressed as the mean ± SEM. Statistical
analyses were carried out by means of the Statistical
Package for Social Sciences (SPSS12.0 J for Windows;
SPSS Japan Inc., Tokyo, Japan). The effects of treatment
were analyzed by the methods as follows. In the five-
group comparison, the variances were calculated by
Levene's test. When the variances were unequal among
the groups, statistical comparisons were made by a non-
parametric test, Kruskal-Wallis test, using post-hoc
Mann–Whitney U tests with the Bonferroni correction.
When the variances were equal among the groups, stat-
istical comparisons were made by a parametric test, one-
way ANOVA, using post-hoc Tukey HSD test. In the
two-group comparison, the variances were calculated by
Levene's test and statistical comparisons were made with
T-test. In OGTT and IPITT, statistical comparisons were
made by means of repeated ANOVA, using post-hoc
Tukey HSD test. Differences were considered significant
at P< 0.05.
Results
Experiment 1
After 12 week of dietary treatment, the final body
weight, the liver weight, the EWAT weight, the soleus
muscle weight and the energy efficiency ratio (EER) were
reduced by FRB dose-dependently (Table 2). Likewise,
the plasma total cholesterol and the hepatic total choles-
terol and triglyceride were reduced by FRB dose-
dependently, whereas no significant difference was found
in the plasma triglyceride (Figure 1A-D). Futhermore,
the fasting blood glucose and plasma insulin levels
decreased significantly in all FRB groups as compared
with the Ctrl and Fen groups. Therefore, homeostasis
model assessment as an index of insulin resistance
(HOMA-IR) decreased significantly in all FRB groups as
compared with the Ctrl and Fen groups (Table 3). And
in the 4.8% FRB group, the area under the curve (AUC)
of glucose in OGTT was significantly reduced as com-
pared with the Ctrl group (Figure 2B). Moreover, the
plasma glucose level decreased remarkably in the 4.8%
FRB group at 120 min in OGTT and IPITT as compared
with the other groups (Figure 2A,C).
Experiment 2
After 12 week of dietary treatment, no significant differ-
ences were found in body weight gain between the FRB
groups and the Ctrl group, whereas the EER, the EWAT
Table 2 Effect of fenugreek on the body weight, energy intake, tissue weights and plasma parameters of experiment 1
Ctrl Fen FRB6
1.2% 2.4% 4.8%
Total energy intake (kJ) 32,156 ± 225a 32,233 ± 175a 32,017 ± 177a 28,789 ± 377b 26,268 ± 1,240b
Final body weight (g) 754 ± 22a 748 ± 16a 714 ± 9a 625 ± 16b 546 ± 19c
EER1 (mg/kJ) 3.95 ± 0.37a 4.05 ± 0.46a 2.75 ± 0.14a 0.80 ± 0.23b −2.98 ± 0.58c
Liver weight (g) 24.2 ± 0.9a 23.2 ± 1.3a 21.5 ± 0.8ab 18.9 ± 0.5bc 16.6 ± 0.5c
EWAT2 weight (g) 23.7 ± 1.3a 23.8 ± 1.1a 21.4 ± 1.2a 12.8 ± 1.2b 7.9 ± 1.0c
Soleuse weight (g) 0.19 ± 0.01ab 0.21 ± 0.01a 0.15 ± 0.02bc 0.13 ± 0.01c 0.11 ± 0.01c
Plasma TG3 (mmol/L) 2.67 ± 0.53 3.05 ± 0.57 4.03 ± 0.64 3.46 ± 0.61 2.93 ± 0.52
Plasma TC4 (mmol/L) 2.00 ± 0.18 1.84 ± 0.15 1.58 ± 0.09 1.45 ± 0.05* 1.29 ± 0.07*
AST (U/L) 65.3 ± 5.4 53.1 ± 2.6 52.3 ± 2.6* 53.3 ± 1.4* 56.0 ± 3.2
ALT (U/L) 22.5 ± 3.3 18.9 ± 1.3 29.6 ± 2.2* 40.1 ± 1.7* 51.8 ± 3.7*
AST/ALT5 1.13 ± 0.09a 1.05 ± 0.09a 0.65 ± 0.02bc 0.49 ± 0.02c 0.04 ± 0.03c
Ctrl: Control group, Fen: Fenugreek group. 1EER (mg/kJ) = Body weight gain (mg)/Total food intake (kJ). 2EWAT: Epididymal white adipose tissue. 3TG: Triglyceride.
4TC: Total cholesterol. 5The relative values for Normal rats' data; AST/ALT =AST (U/L)/ALT (U/L)/Normal rats' data. 6FRB contains 82% of protodioscin converted to
dioscin. Values are expressed as Mean ± SEM for 8 rats. Mean without a common superscript letter is significantly different, P< 0.05 (ANOVA). Asterisks indicate a
difference from Ctrl: P< 0.05 (T-test).
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cholesterol and triglyceride decreased significantly only
in the 1.2% FRB group in comparison with the Ctrl
group (Table 4 and Figure 3B-D). And the soleus muscle
weight and the fecal total cholesterol increased significantlyFigure 1 Effect of FRB on lipids in experiment 1. Hepatic triglyceride [A
cholesterol [D] levels. Ctrl: Control group, Fen: Fenugreek group. 1FRB cont
Mean± SEM for 8 rats. Mean without a common superscript letter is signifi
Ctrl: P< 0.05 (t-test).in the 1.2% FRB group as compared with the Ctrl and Fen
groups (Table 4, Figure 3E,F). Futhermore, the fasting blood
glucose levels decreased significantly in the 1.2% FRB group
as compared with the Ctrl group (Table 5). And the AUC
of glucose in the OGTT significantly decreased in the 1.2%] and total cholesterol [B] levels. Fecal triglyceride [C] and total
ains 82% of protodioscin converted to dioscin. Values are expressed as
cantly different, P< 0.05 (ANOVA). Asterisks indicate a difference from
Table 3 The insulin resistance index of experiment 1
Ctrl Fen FRB4
1.2% 2.4% 4.8%
FBG1 (mmol/L) 5.79 ± 0.29 5.66 ± 0.25 4.93 ± 0.18* 4.78 ± 0.19* 4.98 ± 0.23*
FPI2 (nmol/L) 0.164 ± 0.024a 0.142 ± 0.009b 0.093 ± 0.008ac 0.086 ± 0.010ac 0.081 ± 0.010c
HOMA-IR3 1.10 ± 0.16a 0.93 ± 0.08a 0.52 ± 0.04b 0.47 ± 0.06b 0.45 ± 0.05b
Ctrl: Control group, Fen: Fenugreek group. 1FBG: Fasting blood glucose. 2FPI: Fasting plasma insulin. 3Relative values of (fasting blood glucose × fasting blood
insulin) to the mean value of Ctrl group. 4FRB contains 82% of protodioscin converted to dioscin. Values are expressed as Mean± SEM for 8 rats. Mean without a
common superscript letter is significantly different, P< 0.05 (ANOVA). Asterisks indicate a difference from Ctrl: P< 0.05 (T-test).
Figure 2 Effect of FRB on blood insulin and glucose levels in OGTT and IPITT in experiment 1. Changes of blood glucose [A], AUC of
blood glucose [B], change of plasma insulin [C] and AUC of plasma insulin [D] after oral glucose load (2 g/kg). Change of blood glucose [E] and
AUC of blood glucose [F] after intraperitoneal insulin load (0.75 U/kg). Ctrl: Control group (), Fen: Fenugreek group (), 1.2% FRB group (), 2.4% FRB
group (), 4.8% FRB group ().1FRB contains 82% of protodioscin converted to dioscin. Values are expressed as mean for 8 rats. Asterisks indicate a
difference from Ctrl: P< 0.05 (t-test). [A] shows a significant difference in the 4.8% FRB group for the Ctrl group, and [C] shows a significant
difference in the 2.4% FRB group for the Ctrl group: P< 0.05 (repeated ANOVA).
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Table 4 Effect of fenugreek on the body weight, energy intake, tissue weights and plasma parameters of experiment 2
Ctrl Fen FRB6
0.12% 0.24% 1.2%
Total energy intake (kJ) 34,686 ± 363 35,076 ± 184 35,332 ± 42* 35,119 ± 196* 35,319 ± 40
Final body weight (g) 757 ± 21ab 792 ± 13a 789 ± 18ab 773 ± 16ab 717 ± 14b
EER1 (mg/kJ) 1.54 ± 0.32 2.86 ± 0.31 2.51 ± 0.46 2.38 ± 0.21 0.39 ± 0.52*
Liver weight (g) 21.3 ± 0.9 21.3 ± 1.1 21.6 ± 0.7 21.8 ± 1.4 19.3 ± 0.6
EWAT2 weight (g) 21.0 ± 0.6 23.6 ± 1.4 22.7 ± 1.6 20.3 ± 1.2 15.7 ± 1.5*
Soleuse weight (g) 0.40 ± 0.02 0.44 ± 0.02 0.51 ± 0.08 0.51 ± 0.07 0.54 ± 0.06*
Plasma TG3 (mmol/L) 1.34 ± 0.24 1.73 ± 0.36 1.49 ± 0.34 1.43 ± 0.37 1.27 ± 0.26
Plasma TC4 (mmol/L) 1.95 ± 0.11 1.80 ± 0.05 1.81 ± 0.12 1.76 ± 0.15 1.60 ± 0.09*
AST (U/L) 58.8 ± 4.1 56.5 ± 3.5 52.0 ± 2.9 57.0 ± 4.5 52.4 ± 1.4
ALT (U/L) 19.6 ± 2.0 21.1 ± 2.5 18.3 ± 1.8 20.3 ± 3.5 25.0 ± 4.0
AST/ALT5 1.29 ± 0.18 1.13 ± 0.07 1.18 ± 0.08 1.29 ± 0.21 0.95 ± 0.11
Ctrl: Control group, Fen: Fenugreek group. 1EER (mg/kJ) = Body weight gain (mg)/Total food intake (kJ). 2EWAT: Epididymal white adipose tissue. 3TG: Triglyceride.
4TC: Total cholesterol. 5The relative values for Normal rats' data; AST/ALT =AST (U/L)/ALT (U/L)/Normal rats' data. 6FRB contains 96% of protodioscin converted to
dioscin. Values are expressed as Mean ± SEM for 7–8 rats. Mean without a common superscript letter is significantly different, P< 0.05 (ANOVA). Asterisks indicate
a difference from Ctrl: P< 0.05 (t-test).
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AUC of glucose in the IPTT significantly decreased in the
0.24% FRB group as compared with the Ctrl group
(Figure 4B, F). Moreover, in the OGTT, the plasma glucose
levels in the 1.2% FRB group were significantly lower at 30
and 120 min than those in the Ctrl group (Figure 4A). And
in the IPITT, the plasma glucose levels in the 0.24% FRB
group decreased promptly after the insulin administration
(Figure 4E).
Discussion
Our previous study showed that the effective dose of
fenugreek was around 2.4% (w/w) [12]. The present
study has shown that the effective dose of FRB is lower
than that of fenugreek.
The previous study demonstrated that fiber sources
providing predominantly IDF, such as corn bran, cellu-
lose and wheat bran, have little effect on plasma and
liver cholesterol levels. On the other hand, fiber sources
containing a mixture of both SDF and IDF, such as soy-
bean and oat bran, have intermediate effects on plasma
and liver cholesterol levels [19]. SDF may be fermentable
in the large intestine by the action of colonic bacteria
producing short chain fatty acids such as butyrate,Table 5 The insulin resistance index of experiment 2
Ctrl Fen
FBG1 (mmol/L) 5.70 ± 0.24 5.93 ± 0.40 5.
FPI2 (nmol/L) 0.178 ± 0.045 0.235 ± 0.052 0.1
HOMA-IR3 1.00 ± 0.24 1.47 ± 0.39 0.
Ctrl: Control group, Fen: Fenugreek group. 1FBG: Fasting blood glucose. 2FPI: Fasting
insulin) to the mean value of Ctrl group. 4FRB contains 96% of protodioscin convert
a common superscript letter is significantly different, P< 0.05 (ANOVA). Asterisks inpropionate, acetate etc. [20], which can act to reduce
cholesterol synthesis [21]. And the major functions of
IDF fractions can be attributed to their passive water
holding capacity and non-digestibility, which may help
to increase the bulk and shortens the transit time of
stool through the intestinal tract [22]. However, IDF
showed no effect on cholesterol absorption. The increase
of SDF fraction in FRB might induce remarkable lower-
ing effects on plasma and liver cholesterol concentra-
tions [23].
On the other hand, many reports have been published,
and demonstrated that diosgenin (aglycon of protodioscin
and dioscin) had effects on glucose and lipid metabolism.
Diosgenin raises the peroxisome proliferator-activated re-
ceptor γ (PPARγ) level in WAT, and promotes adipocyte
differentiation and size reduction of adipocytes. As a re-
sult, the secretion of monocyte chemoattractant protein-1
(MCP-1) in adipocytes is suppressed, whereas the secre-
tion of adiponectin is promoted, and the inflammation in
adipose tissue is inhibited [13,24]. Therefore, diosgenin is
also a candidate component to be contained in fenugreek
for the improvement of insulin sensitivity. In addition,
saponins, such as diosgenin, form large micelles from bile
acid and saponin molecules in the small intestine, andFRB4
0.12% 0.24% 1.2%
69 ± 0.30 5.21 ± 0.22 4.95 ± 0.25*
76 ± 0.029 0.368 ± 0.095 0.165 ± 0.018
97 ± 0.12 1.88 ± 0.51* 0.81 ± 0.08
plasma insulin. 3Relative values of (fasting blood glucose × fasting blood
ed to dioscin. Values are expressed as Mean± SEM for 7–8 rats. Mean without
dicate a difference from Ctrl: P< 0.05 (T-test).
Figure 3 Effect of FRB on lipids in experiment 2. Hepatic triglyceride [A] and total cholesterol [B] levels. Fecal triglyceride [C] and total
cholesterol [D] levels. Ctrl: Control group, Fen: Fenugreek group. 1FRB contains 96% of protodioscin converted to dioscin. Values are expressed as
Mean± SEM for 7–8 rats. Mean without a common superscript letter is significantly different, P< 0.05 (ANOVA). Asterisks indicate a difference
from Ctrl: P< 0.05 (t-test).
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ectly excreting it in feces [25,26]. Diosgenin also reduces
the triglyceride content and mRNA expression levels of
lipogenic genes (FAS, SCD-1 and ACC) and suppresses
the LXRα transactivation, leading to the down-regulation
of both the mRNA and protein expression levels of
SREBP-1c in HepG2 cells [27]. Thus, diosgenin is consid-
ered to be an active ingredient. However, a major part of
protodioscin was converted by the enzyme into dioscin in
the FRB. Therefore, in our study, dioscin as well as dios-
genin may have contributed to the improvement of glu-
cose and lipid metabolism.
There was a discrepancy of plasma triglyceride levels
between the two experiments. We suspect that the
longer period of fasting before the sacrifice in the experi-
ment 2 might have induced the low levels of plasma
triglyceride.
The results of the experiment 1 and 2 suggested that
FRB had effect on lipid metabolism and glucose toler-
ance in the 1.2%, 2.4% and 4.8% FRB groups. In the ex-
periment 1, appetite declined significantly in the 2.4%
and 4.8% FRB groups. And the soleus muscle weight and
urinary creatinine levels (data not shown), which were
related to the muscle mass as well as EWAT weight,decreased in these two groups. In addition, the plasma
albumin and protein levels decreased in the 4.8% FRB
group as compared with the Ctrl group (data not
shown). Furthermore, the plasma insulin levels were
relatively high, which led to the very low level of blood
glucose at 120 min in the 4.8% FRB group. These results
suggested that overdose of FRB induced a body and
muscle weight reduction, and caused a dangerous
hypoglycemia.
We have demonstrated that 1.2% or more of FRB pre-
vents diet-induced metabolic disorders including insulin
resistance, dyslipidemia and fatty liver. The effective and
safe dose of FRB is around 1.2% (w/w) contained in the
diet (~ 0.25 g/kg BW/day).
Additional file
Additional file 1: The English version of reference 13. Reference 13
derives from the abstract in Japanese of the original presentation. Here
we translated it into English.
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